Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 2

Клиническая эффективность реслизумаба у отдельных групп пациентов с тяжелой бронхиальной астмой
Д.С. Фомина, Е.Н. Бобрикова, С.В. Федосенко

References

1. Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergology International 2019 Apr;68(2):158-66.
2. Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs 2014 May;74(7):719-28.
3. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, Casale TB, Chan-Yeung M, Chen R, Chowdhury B, Chung KF, Dahl R, Drazen JM, Fabbri LM, Holgate ST, Kauffmann F, Haahtela T, Khaltaev N, Kiley JP, Masjedi MR, Mohammad Y, O’Byrne P, Partridge MR, Rabe KF, Togias A, van Weel C, Wenzel S, Zhong N, Zuberbier T. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. The Journal of Allergy and Clinical Immunology 2010;126:926-38.
4. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2019. Available from: https://ginasthma.org/gina-reports/ Accessed 2019 Sep 18.
5. Ilyina NI, Nenasheva NM, Avdeyev SN, Aysanov ZR, Arkhipov VV, Viezel AA, Yemelyanov AV, Knyazheskaya NP, Kurbacheva OM, Leshchenko IV, Osipova GL, Styrt EA, Titova ON, Fassakhov RS, Fedosenko SV. Algorithm of biophenotyping and choice of medication for targeted therapy of severe uncontrolled bronchial asthma with eosinophilic type of airways inflammation. Russian Journal of Allergy 2017;14(3):5-18 (In Russian).
6. Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respiratory Research 2018 Jan;19(1):12.
7. Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, Peche R, Manise M, Joos G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respiratory Medicine 2014 Dec;108(12):1723-32.
8. Carr TF, Berdnikovs S, Simon HU, Bochner BS, Rosenwasser LJ. Eosinophilic bioactivities in severe asthma. The World Allergy Organization Journal 2016 Jun;9:21.
9. de Groot JC, ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. European Respiratory Journal Open Research 2015 Sep;1(1). pii: 00024-2015. eCollection 2015 May.
10. Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, Gjomarkaj M, Gaga M, Brusselle G, Dahlén B, Dahlén SE; BIOAIR investigators. Frequent exacerbators – a distinct phenotype of severe asthma. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2014 Feb;44(2):212-21.
11. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. The Journal of Allergy and Clinical Immunology 2010 May;125(5):1028-36.e13.
12. Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology 2014 Jul;113(1):19-24.
13. Bateman ED, Zangrilli J, Germinaro M, Weiss S, Castro M. Association between early improvements in lung function and asthma control with reslizumab and the annual rate of asthma exacerbations. American Journal of Respiratory and Critical Care Medicine 2016;193:A7782.
14. Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, Segal M, Fahy JV. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. The Journal of Allergy and Clinical Immunology 2001 Nov;108(5):753-8.
15. Bateman ED, Djukanović R, Castro M, Canvin J, Germinaro M, Noble R, Garin M, Buhl R. Predicting responders to reslizumab after 16 weeks of treatment using an algorithm derived from clinical studies of patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine 2019 Feb;199(4):489-95.
16. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. The Journal of Allergy and Clinical Immunology 2004;113(1):101-8.
17. Skolnik NS, Carnahan SP. Primary care of asthma: new options for severe eosinophilic asthma. Current Medical Research and Opinion 2019 Jul;35(7):1309-18.
18. Fassakhov RS. Severe eosinophilic bronchial asthma: therapeutic potential of reslizumab. Medical Council 2018;15:70-5 (In Russian).
19. Egan RW, Athwal D, Bodmer MW, Carter JM, Chapman RW, Chou CC, Cox MA, Emtage JS, Fernandez X, Genatt N, Indelicato SR, Jenh CH, Kreutner W, Kung TT, Mauser PJ, Minnicozzi M, Murgolo NJ, Narula SK, Petro ME, Schilling A, Sehring S, Stelts D, Stephens S, Taremi SS, Zurcher J. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittel-Forschung 1999 Sep;49(9):779-90.
20. Liddament M, Husten J, Estephan T, Laine D, Mabon D, Pukac L, Lyons J, Clarke AW, Doyle A. Higher binding affinity and in vitro potency of reslizumab for interleukin-5 compared with mepolizumab. Allergy Asthma & Immunology Research 2019 Mar;11(2):291-8.
21. Ilyina NI. An issue of selecting of immunobiological therapy of bronchial asthma. Russian Journal of Allergy 2019;16(1-1):9-12 (In Russian).
22. Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quirce S, Virchow JC, Holgate S; expert group of the European Consensus Meeting for Severe Eosinophilic Asthma. Severe eosinophilic asthma: a roadmap to consensus. The European Respiratory Journal 2017 May;49(5). pii: 1700634. doi: 10.1183/13993003.00634-2017.
23. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 2011 Nov;184(10):1125-32.
24. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet. Respiratory Medicine 2015 May;3(5):355-66.
25. Henriksen DP, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H, Andersson EA, Norgaard O, Madsen LK, Chawes BL Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis. European Clinical Respiratory Journal 2018 Nov;5(1):1536097.
26. Agumadu VC, Ramphul K, Mejias SG, Sonaye R, Sombans S, Lohana P. A review of three new anti-interleukin-5 monoclonal antibody therapies for severe asthma. Curēus 2018 Aug;10(8):e3216.
27. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016 Oct;150(4):799-810.
28. Padilla Galo A, Labor M, Tiotiu A, Baiardini I, Scichilone N, Braido F. Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives. Patient Related Outcome Measures 2018 Aug;9:267-73.
29. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016 Oct;150(4):789-98.
30. Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M. Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. The Journal of Allergy and Clinical Immunology. In Practice 2019 Jan;7(1):122-30.e1.
31. Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, Castro M. Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials. The Journal of Allergy and Clinical Immunology. In Practice 2019 Aug. pii: S2213-2198(19)30701-9. doi: 10.1016/j.jaip.2019.07.038.
32. He LL, Zhang L, Jiang L, Xu F, Fei DS. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis. International Immunopharmacology 2018 Nov;64:223-31.
33. Nair P, Bardin P, Humbert M, Murphy KR, Hickey L, Garin M, Vanlandingham R, Chanez P. Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma. The Journal of Allergy and Clinical Immunology. In Practice 2019 Oct. pii: S2213-2198(19)30865-7. doi: 10.1016/j.jaip.2019.09.036.
34. Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. The Journal of Allergy and Clinical Immunology. In Practice 2019 Feb;7(2):589-96.e3.
35. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P, Bachert CJ. The Journal of Allergy and Clinical Immunology 2006 Nov;118(5):1133-41.
36. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine 2012 May;18(5):716-25.
37. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology & Therapeutics 2017 Apr;43:39-45.
38. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. American Journal of Respiratory and Critical Care Medicine 2019 Feb;199(4):433-45.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]